BiotechTube

Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COPD

Conditions

COPD

Trial Timeline

Oct 1, 2003 → May 1, 2004

NCT ID
NCT00691405

About Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo

Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo is a phase 2 stage product being developed by Sumitomo Pharma for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT00691405. Target conditions include COPD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00691405Phase 2Completed

Competing Products

20 competing products in COPD

See all competitors
ProductCompanyStageHype Score
Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
85
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
Lysozyme hydrochloride + PlaceboEisaiApproved
85
Arformoterol (Brovana) + PlaceboSumitomo PharmaApproved
85
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + PlaceboSumitomo PharmaPhase 3
77
Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
85
Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterolSumitomo PharmaPhase 2
52
Levalbuterol HCl + Levalbuterol HCl + Albuterol Sulfate + PlaceboSumitomo PharmaPhase 3
77
Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol TurbuhalerAstraZenecaPhase 1
33
AZD2115 + Placebo + Indacaterol + Indacaterol + TiotropiumAstraZenecaPhase 2
52
RoflumilastAstraZenecaPhase 2/3
65
Aclidinium bromide + PlaceboAstraZenecaPhase 3
77
RoflumilastAstraZenecaPre-clinical
23
Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)AstraZenecaApproved
85
AZD7624 + Placebo to matchAstraZenecaPhase 1
33
Roflumilast + PlaceboAstraZenecaPhase 3
77
Aclidinium bromide 100 μg bid + Aclidinium bromide 200 μg bid + Aclidininum bromide 400 μg bid + Placebo + Formoterol 12 μg bidAstraZenecaPhase 2
52
ACL/FOR + PlaceboAstraZenecaApproved
85
TozorakimabAstraZenecaPhase 2
52
AZD1981 + PlaceboAstraZenecaPhase 2
52

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85